Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML

by NASDAQ Market News June 7, 2021

NASDAQ Market News
Click here to email author

UCSF QBI and University College, London Identify Mutations in “U.K.” Strain of Coronavirus SARS-CoV-2 Responsible for Enhanced Transmissibility and Infectivity

Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual Meeting

Ads